Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of $1.25, $1.54 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $90.06 million versus the consensus estimate of $20.63 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.